Granting “orphan” drug status to Gilead Sciences for remdesivir, its potential coronavirus treatment, is a massive boon to the company.
Read more...If the public is to be asked to give bailouts to businesses, it should get something back for its money. It needs to share in any upside.
Read more...The State Department’s global level 4 health advisory,recommending US citizens not travel internationally, has travel insurance implications.
Read more...The bailout bill looks shameless, even by Trump Administration standards.
Read more...The COVID-19 specter led Congresscritters to coo reassurance, and dump shares. A modest proposal: require immediate disclosure of trades.
Read more...How McKinsey put money over its once vaunted firm values.
Read more...Voter disenfranchisement via shuttering polling sites.
Read more...Jeff Bezos continues to abuse his workers, this time (or more accurately, again) at Whole Foods.
Read more...CalPERS apparently needs to take a bath on its legacy assets.
Read more...Citi is doing a number on its own and the Mastercard brand name with cringe-makingly inept and dishonest credit card operations.
Read more...Yves here. When we made grim prognostications about Boeing’s future, we were treated as nuts. By Wolf Richter, editor at Wolf Street. Originally published at Wolf Street Boeing’s shares [BA] came unglued, plunging 18.1% today, after having already plunged over the past four weeks. Since February 12, shares have crashed 46%, and since the peak […]
Read more...How more IoT = more messed up elections
Read more...Is the seamy side of fracking the only side?
Read more...How the ordering of the world to suit the 1% – also known as plutonomy – has generated long-overdue “populist” pushback.
Read more...The UK told a very big fib about its Porton Down lab….and it looks like it matters.
Read more...